Search details
1.
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.
Ann Oncol
; 30(9): 1507-1513, 2019 09 01.
Article
in English
| MEDLINE | ID: mdl-31240310
2.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Ann Oncol
; 29(5): 1203-1210, 2018 05 01.
Article
in English
| MEDLINE | ID: mdl-29635390
3.
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Ann Oncol
; 28(4): 761-768, 2017 04 01.
Article
in English
| MEDLINE | ID: mdl-28057664
4.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 28(1): 128-135, 2017 01 01.
Article
in English
| MEDLINE | ID: mdl-28177460
5.
Oncologist use and perception of large panel next-generation tumor sequencing.
Ann Oncol
; 28(9): 2298-2304, 2017 Sep 01.
Article
in English
| MEDLINE | ID: mdl-28911072
6.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Ann Oncol
; 28(8): 1700-1712, 2017 08 01.
Article
in English
| MEDLINE | ID: mdl-28838210
7.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 27(8): 1519-25, 2016 08.
Article
in English
| MEDLINE | ID: mdl-27177864
8.
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
Breast Cancer Res Treat
; 158(1): 91-97, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27306421
9.
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Ann Oncol
; 26(7): 1494-500, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25851628
10.
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Breast Cancer Res Treat
; 151(3): 597-606, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25981896
11.
The AURORA initiative for metastatic breast cancer.
Br J Cancer
; 111(10): 1881-7, 2014 Nov 11.
Article
in English
| MEDLINE | ID: mdl-25225904
12.
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
Ann Oncol
; 30(6): 1021, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30624607
13.
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Ann Oncol
; 25(6): 1116-21, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24685829
14.
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Ann Oncol
; 30(6): 1019, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30624581
15.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Ann Oncol
; 25(3): 592-598, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24401928
16.
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
Ann Oncol
; 25(8): 1656-63, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24827126
17.
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Ann Oncol
; 30(8): 1404, 2019 08 01.
Article
in English
| MEDLINE | ID: mdl-30624595
18.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Ann Oncol
; 30(7): 1178, 2019 07 01.
Article
in English
| MEDLINE | ID: mdl-30624599
19.
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
Ann Oncol
; 30(6): 1020, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30624604
20.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 30(7): 1180, 2019 07 01.
Article
in English
| MEDLINE | ID: mdl-30624609